Logo
Nazad
Edin Muratspahić, David Feldman, David E. Kim, Xiangli Qu, A. Bratovianu, Paula Rivera-Sánchez, Federica Dimitri, Jason Cao, Brian P. Cary, M. Belousoff, Peter Keov, Qingchao Chen, Yue Ren, Justyn Fine, Isaac Sappington, Thomas Schlichthaerle, Jason Z. Zhang, Arvind Pillai, Ljubica Mihaljević, Magnus Bauer, Susana Vázquez Torres, Amir Motmaen, Gyu Rie Lee, Long Tran, Xinru Wang, Inna Goreshnik, Dionne K. Vafeados, Justin E. Svendsen, Parisa Hosseinzadeh, Nicolai Lindegaard, Matthäus Brandt, Yann Waltenspühl, Kristine Deibler, Luke Oostdyk, William Cao, L. Anantharaman, Lance Stewart, Lauren Halloran, Jamie B. Spangler, P. Sexton, Bryan L. Roth, Brian E. Krumm, D. Wootten, Christopher G. Tate, Christoffer H Norn, David Baker
2 5. 6. 2025.

De novo design of miniprotein agonists and antagonists targeting G protein-coupled receptors

G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development, yet the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic. Here we describe computational de novo design methods and a high throughput “receptor diversion” microscopy-based screen for generating GPCR binding miniproteins with high affinity, potency and selectivity, and the use of these methods to generate MRGPRX1 agonists and CXCR4, GLP1R, GIPR, GCGR and CGRPR antagonists. Cryo-electron microscopy data reveals atomic-level agreement between designed and experimentally determined structures for CGRPR-bound antagonists and MRGPRX1-bound agonists, confirming precise conformational control of receptor function. Our de novo design and screening approach opens new frontiers in GPCR drug discovery and development.


Pretplatite se na novosti o BH Akademskom Imeniku

Ova stranica koristi kolačiće da bi vam pružila najbolje iskustvo

Saznaj više